Synthetic progestin drospirenone containing oral contraceptives may carry a higher risk for venous thromboembolism than pills with other types of progestins.
This announcement was made today by the US Food and Drug Administration announced today.
FDA is adding information about the studies to the labels of drospirenone containing birth control pills. The labels would report that some epidemiologic studies reported as high as a three-fold increase in the risk of blood clots for drospirenone containing products when compared to products containing levonorgestrel or some other progestins, whereas other epidemiological studies found no additional risk of blood clots with drospirenone containing products.
The labels also will include a summary of the previously released results of an FDA-funded study of the blood clot risk.
It is unclear whether the increased risk seen for blood clots in some of the epidemiologic studies is actually due to drospirenone-containing birth control pill but the conclusion based on available data mentions that the risk may be higher for these pills.
Source : Announcement on FDA website
